Prurigo nodularis
☆ Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
References
Mae Prurigo nodularis yn gyflwr croen parhaol a nodweddir gan bumps a nodwlau cadarn lluosog, a geir fel arfer ar rannau allanol y breichiau a'r coesau. Gall y lympiau hyn amrywio o ran lliw o gnawd-liw i binc ac maent yn cosi'n fawr. Gallant effeithio ar bobl o unrhyw oedran ac maent yn aml yn gysylltiedig â chyflyrau croen eraill sy'n achosi cosi cronig, fel dermatitis atopig. Mae opsiynau triniaeth yn cynnwys meddyginiaethau gwrth-cosi cryf, cyffuriau sy'n effeithio ar y system imiwnedd, a meddyginiaethau sy'n targedu'r system nerfol. Mae rheoli'r prurigo nodularis fel arfer yn cynnwys therapi hirdymor.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Mae triniaeth fel arfer yn cynnwys defnyddio hufenau neu bigiadau o steroidau ar yr ardal yr effeithir arni. Mewn achosion mwy difrifol neu ystyfnig, efallai y bydd angen triniaethau fel therapi ysgafn neu feddyginiaethau sy'n atal y system imiwnedd. Mae thalidomide a lenalidomide yn opsiynau ar gyfer achosion difrifol, ond gallant gael sgîl-effeithiau difrifol. Mae triniaethau mwy newydd (opioid receptor antagonists, neurokinin-1 receptor antagonists) yn dangos addewid wrth drin prurigo nodularis gyda llai o sgîl-effeithiau o'i gymharu â thalidomide neu lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Mae Chronic prurigo yn gyflwr croen a nodweddir gan gosi hirhoedlog (sy'n para dros 6 wythnos) , briwiau croen sy'n gysylltiedig â chrafu, a hanes o grafu aml. Mae'n cynnwys niwro-lid a ffibrosis yn y croen.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Mae Prurigo nodularis yn broblem croen hirhoedlog a nodir gan nodiwlau coslyd. Nid ydym yn gwybod yn union beth sy'n ei achosi, ond mae'n ymddangos bod materion imiwnedd a nerfau yn chwarae rhan yn y cylch cosi-crafu. Ar hyn o bryd, nid oes unrhyw driniaethau wedi'u cymeradwyo gan FDA yr UD yn benodol ar gyfer prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Triniaeth ― OTC Drugs
Nid yw golchi ardal y briw â sebon yn helpu o gwbl a gall ei waethygu. Gall eli steroid OTC helpu i leddfu'r symptomau, ond fel arfer mae angen eu cymhwyso am sawl wythnos i wella. Mae parhau i gymryd gwrth-histaminau hefyd yn helpu i leddfu'r cosi.
#OTC steroid ointment
#OTC antihistamine
○ Triniaeth
#Intralesional triamcinolone injection